Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2005

View Archived Issues

Interferon beta products reported to be equally effective in multiple sclerosis

Doripenem shows efficacy against multidrug-resistant bacilli from cystic fibrosis patients

LA-12 shows potent antitumor efficacy in a 5-day treatment in mice

WM-13 triggers apoptosis in prostate cancer cell lines

Human urotensin-II receptor antagonists reported

Meta-analysis of opioid use for the treatment of neuropathic pain

Immunosuppressive action of 4OH-OPB

Gentium's CMC submission adequate for phase III trial of defibrotide

Biosite licenses novel renal injury marker NGAL

Tarceva receives Canadian approval for advanced NSCLC

Factor 5A inhibits lung tumor formation in mice

Merck KGaA to acquire UFT rights

Takeda acquires PPD's rights to DPP-IV inhibitors

HDAC inhibitor CRA-024781 enters phase I

CVT-6883 enters clinical program for asthma

Ligand earns milestone for phase II studies of LY-674

Amplimexon plus dacarbazine studied for melanoma

PRX-03140 enters phase Ib study in Alzheimer's patients

Avax begins two cancer trials

Three-year extension to collaboration between Structural GenomiX and Lilly

Cellular Genomics selects development candidate, changes corporate name

Migenix and Schering-Plough sign agreement for MX-3253

Concomitant therapy with new SODm M-40403 may enable dose reduction of steroids

Role of tyrosine kinases identified in poxvirus replication

New agents for diabetes and related conditions reported in recent patents

Compounds for schizophrenia, anxiety, depression, etc. revealed in patents

Cysteine protease cathepsin inhibitors from Celera Genomics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...